ENDRA Life Sciences Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Alexander Tokman (CEO/Chairman) and Richard Jacroux (CFO) certified the Q2 2026 10-Q filing as of June 30, 2026 on August 14, 2026, affirming accuracy of financial statements, effectiveness of disclosure controls and internal controls, and absence of material misstatements or fraud. The certifications are standard boilerplate Sections 302 and 906 attestations required by Sarbanes-Oxley; no specific operational, financial, or structural changes are disclosed in this excerpt.
Why this rating
Certification exhibits are mandatory periodic disclosures with zero substantive business content; no transactions, guidance changes, or material events are described.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.